REVENUES (Tables)

6 Months Ended

Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Summary of Disaggregation of Revenues

The following table summarizes our Total revenues:

	Three Months Ended June 30, 2024								Three Months Ended June 30, 2023
(in millions)	U.S.		Europe		Rest of World		Total		U.S.		Europe		Rest of World		Total
Product sales:
HIV
Biktarvy	$	2,585	$	370	$	277	$	3,232	$	2,439	$	302	$	237	$	2,979
Descovy	434		25		26		485		460		25		31		516
Genvoya	372		45		23		440		455		56		29		540
Odefsey	233		72		10		315		267		74		11		351
Symtuza - Revenue share(1)	131		34		3		168		84		33		3		120
Other HIV(2)	65		25		15		105		74		31		15		120
Total HIV	3,821		571		353		4,745		3,778		521		326		4,626
Liver Disease
Sofosbuvir/Velpatasvir(3)	267		84		126		476		223		84		90		397
Vemlidy	117		11		115		243		96		10		113		219
Other Liver Disease(4)	47		47		19		113		37		37		21		95
Total Liver Disease	431		142		259		832		356		131		225		711
Veklury	76		53		85		214		97		52		107		256
Oncology
Cell Therapy
Tecartus	63		37		7		107		56		29		4		88
Yescarta	186		169		58		414		217		133		30		380
Total Cell Therapy	250		206		66		521		272		162		34		469
Trodelvy	224		69		26		320		189		53		17		260
Total Oncology	474		275		92		841		462		215		51		728
Other
AmBisome	17		69		65		151		20		69		61		151
Other(5)	98		8		24		130		64		10		17		92
Total Other	115		77		88		280		85		80		78		243
Total product sales	4,916		1,118		878		6,912		4,777		999		788		6,564
Royalty, contract and other revenues	25		15		1		41		6		28		1		35
Total revenues	$	4,941	$	1,133	$	879	$	6,954	$	4,784	$	1,027	$	789	$	6,599

	Six Months Ended June 30, 2024								Six Months Ended June 30, 2023
(in millions)	U.S.		Europe		Rest of World		Total		U.S.		Europe		Rest of World		Total
Product sales:
HIV
Biktarvy	$	4,900	$	735	$	542	$	6,177	$	4,600	$	606	$	449	$	5,656
Descovy	805		51		55		911		855		50		60		965
Genvoya	704		95		44		843		872		111		58		1,041
Odefsey	457		148		21		626		497		149		22		668
Symtuza - Revenue share(1)	236		67		6		309		182		70		7		259
Other HIV(2)	125		70		27		222		136		63		28		228
Total HIV	7,226		1,167		695		9,088		7,142		1,049		624		8,816
Liver Disease
Sofosbuvir/Velpatasvir(3)	515		163		203		881		427		174		181		782
Vemlidy	212		22		233		467		183		19		216		418
Other Liver Disease(4)	89		94		38		221		64		78		44		186
Total Liver Disease	816		279		474		1,569		674		271		441		1,386
Veklury	391		123		255		769		349		163		317		829
Oncology
Cell Therapy
Tecartus	118		73		16		207		114		56		6		177
Yescarta	357		327		110		794		427		254		58		739
Total Cell Therapy	475		400		126		1,001		542		310		65		916
Trodelvy	429		137		62		628		351		107		23		482
Total Oncology	904		537		188		1,629		893		417		88		1,398
Other
AmBisome	31		139		124		294		27		129		111		267
Other(5)	156		18		36		209		127		22		26		175
Total Other	188		156		160		504		153		152		137		442
Total product sales	9,525		2,262		1,772		13,559		9,211		2,052		1,607		12,870
Royalty, contract and other revenues	49		30		2		81		25		54		3		81
Total revenues	$	9,574	$	2,292	$	1,774	$	13,640	$	9,236	$	2,106	$	1,610	$	12,951

_______________________________

(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).

(2)    Includes Atripla, Complera/Eviplera, Emtriva, Sunlenca, Stribild, Truvada and Tybost.

(3)    Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).

(4)    Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Sovaldi, Viread and Vosevi.

(5)    Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig.

Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods

The following table summarizes revenues recognized from performance obligations satisfied in prior years:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
(in millions)	2024		2023		2024		2023
Revenue share with Janssen and royalties for licenses of intellectual property	$	202	$	158	$	372	$	350
Changes in estimates	$	82	$	77	$	242	$	237

Summary of Contract Balances

The following table summarizes our contract balances:

(in millions)	June 30, 2024		December 31, 2023
Contract assets(1)	$	165	$	117
Contract liabilities(2)	$	76	$	109

________________________________

(1)    Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation.

(2)    Generally results from receipt of advance payment before our performance under the contract.